This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MarketVIEW: Acne Vaccines





NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Acne vaccines

http://www.reportlinker.com/p0961702/MarketVIEW-Acne-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Acne vulgaris is a common skin condition which is estimated to affect 80% of people at some point between 11 and 30 years of age. The condition ranges from mild to severe with latter more likely to cause scarring and psychological impact such as depression, loss of self esteem and in extreme cases, suicidal ideation. Acne is responsible for a significant number of yearly physician office visits and direct costs for treatments which range from OTC lotions to prescription based antibiotics/retinoids. 

An acne vaccine targeting the main causative bacterium P.acnes could have wide utility if it prevents inflammatory outbreaks in individuals suffering from acne. Indeed, the major vaccine manufacturer Sanofi Pasteur has already announced interest in this concept ( University of San Diego collaboration) confirming its potential attractiveness. 

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of acne vaccines (value/volume) to 2030 in the Western region. The product examines different uptake scenarios of the vaccine in severe and non-severe patient groups at different age range(s). Detailed coverage of latest acne epidemiology is included, also a focus on current treatment pathways, costs and the need for a novel vaccine approach. This product is an essential component of any new internal exercise assessing the potential of new acne vaccines. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL Contents – Executive presentation (MS PowerPoint based)Title PageContentsAuthor's notesExecutive SummaryCommercial model: key outputsAcne vaccine: available market ($ 000s) to 2030 (severe patients)Acne vaccine: predicted volume (doses 000s) to 2030 (severe patients)Acne vaccine: available market ($ 000s) to 2030 per country (severe patients)Acne vaccine: available market ($ 000s) to 2030 (all patients)Acne vaccine: predicted volume (doses 000s) to 2030 (all patients)Acne vaccine: available market ($ 000s) to 2030 (BASE SCENARIO)Acne vaccine: predicted volume (doses 000s) to 2030 (BASE SCENARIO)Acne Vulgaris: disease background and epidemiologyAcne: brief disease backgroundAcne: clinical typesAcne: global epidemiologyAcne: adult acne statisticsAcne: impact of the diseaseAcne: treatment pathwayAcne: treatment overviewAcne: treatment optionsAcne: effectiveness of treatment in mild and moderate casesAcne: effectiveness of treatment in severe casesAcne: cost of treatmentAcne: cost of treatment in the USAcne vaccine; target product profile (TPP)The role of an acne vaccineCurrent status of the vaccinePipeline summaryAddressable vaccine populationsAcne vaccine forecast modelForecast vaccine population flowAcne vaccine: target product profileCommercial model assumptionsDetailed commercial model assumptions by country (LO uptake)Detailed commercial model assumptions by country (BASE uptake)Acne vaccine: other target populationsBibliographyDisclaimerAbout VacZine AnalyticsPAGES: ~50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model(s) (MS Excel-based)Note: further models can be included with differing vaccine price scenariosTitle pageTOTAL CHARTS (ALL PATIENTS)TOTAL CHARTS (severe only)BASE (severe versus non-severe)CHARTS – VAL HIGH (severe only)CHARTS – VAL BASE (severe only)CHARTS – VAL LOW (severe only)CHARTS – VOL HIGH (severe only)CHARTS – VOL BASE (severe only)CHARTS – VOL LOW (severe only)VALUE SUMMARY (severe only)VOLUME SUMMARY (severe only)VALUE SUMMARY (ALL PATIENTS)VOLUME SUMMARY (ALL PATIENTS)Country worksheets =>>USCANADAUKFRANCEGERMANYITALYSPAINAUSTRALIAJAPANAssumptionsWorksheets = 44 per model

To order this report:: MarketVIEW: Acne vaccines



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,056.71 -14.51 -0.08%
S&P 500 1,977.80 0.00 0.00%
NASDAQ 4,507.1070 +1.2550 0.03%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs